| scholarly article | Q13442814 |
| P2093 | author name string | Velimir A Luketic | |
| Marion G Peters | |||
| Danyu Lin | |||
| Guadalupe Garcia-Tsao | |||
| Robert L Carithers | |||
| Santiago J Munoz | |||
| Burton Combes | |||
| Rowen K Zetterman | |||
| Nancy Flye | |||
| P2860 | cites work | The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis | Q49110706 |
| A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis | Q51586165 | ||
| Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group. | Q54118475 | ||
| Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis | Q71035932 | ||
| Ursodeoxycholic acid in the treatment of primary biliary cirrhosis | Q72401649 | ||
| A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group | Q28243457 | ||
| Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis | Q33745849 | ||
| Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis) | Q39859200 | ||
| Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis | Q40883127 | ||
| Ursodeoxycholic acid treatment in patients with primary biliary cirrhosis. A Swedish multicentre, double-blind, randomized controlled study | Q42551010 | ||
| Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis? | Q49100848 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | primary biliary cholangitis | Q1072420 |
| multicenter clinical trial | Q6934595 | ||
| P304 | page(s) | 264-268 | |
| P577 | publication date | 2004-02-01 | |
| P1433 | published in | The American Journal of Gastroenterology | Q7713501 |
| P1476 | title | Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis | |
| P478 | volume | 99 |
| Q36752084 | Current Concepts in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis |
| Q56429943 | Guidelines for the management of primary biliary cirrhosis |
| Q37738636 | Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis |
| Q34550505 | Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials |
| Q45250878 | Long-term ursodeoxycholic acid therapy for primary biliary cirrhosis: a follow-up to 12 years. |
| Q36197335 | Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: ursodeoxycholic acid freezes regeneration & induces hibernation mode. |
| Q46719878 | Mortality attributable to cholestatic liver disease in the United States. |
| Q92565000 | Neonatal cholestasis: emerging molecular diagnostics and potential novel therapeutics |
| Q38738566 | Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis. |
| Q84230884 | Primary biliary cirrhosis |
| Q33730935 | Recurrent primary biliary cirrhosis: peritransplant factors and ursodeoxycholic acid treatment post-liver transplant |
| Q36801651 | Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses |
| Q24202184 | Ursodeoxycholic acid for primary biliary cirrhosis |
Search more.